Blida

Researchers are conducting a prospective, multicenter observational study called SAFRO 2202 ALG-Lung Cancer Registry to gather detailed information on lung cancer patients in Algeria. This study focuses on various types of lung cancer, including non-small cell lung cancer, small cell lung cancer, and carcinoid tumors. The goal is to collect real-world data on the epidemiology, clinical features, pathology, molecular markers, and treatment patterns to improve lung cancer care nationwide. The study involves adult patients aged 18 years and older who have been diagnosed with lung cancer at the time of enrollment or within the prior 12 months. Participants are managed fully within oncology or pulmonology departments at 21 public and university hospitals across Algeria. Data are collected during routine clinical care visits without any additional study-specific procedures or interventions. Information such as tumor histology, molecular profiles, staging, and treatment choices are recorded securely in an electronic case report form. During the study, researchers will track clinical outcomes including treatment toxicities, response rates, progression-free survival, time to treatment discontinuation, and overall survival. Data collection aligns with standard care and includes demographic details, medical history, risk factors, and performance status. The study plans to enroll about 1,500 patients per year over 30 months, with each patient followed for at least 12 months to support future health planning and lung cancer management improvements in Algeria.

Researchers are evaluating the effectiveness and tolerability of the subcutaneous combination of trastuzumab and pertuzumab Phesgo as neoadjuvant treatment in Algerian women with early-stage, HER2-positive breast cancer. This observational study will include about 70 adult women diagnosed with non-metastatic HER2-positive breast cancer and aims to assess how well this treatment works before surgery. Participants will receive Phesgo alongside standard chemotherapy for approximately 18 weeks before undergoing surgery. The study takes place in three oncology centers across Algeria and focuses on real-world application to see if this treatment can simplify delivery, reduce hospital burden, and improve access to care in areas with limited healthcare resources. During the study, researchers will monitor outcomes including the rate of complete destruction of invasive cancer in the breast and nearby lymph nodes at surgery, the rate of breast-conserving surgery, incidence of side effects, patient satisfaction with treatment, and factors predicting treatment response. Follow-up assessments will occur from treatment start through surgery and shortly after, with safety monitored until 30 days after the last dose.

Researchers are evaluating the combination of Palbociclib and hormone therapy Letrozole or Anastrozole in women with newly diagnosed metastatic luminal hormone receptor-positive and HER2 negative breast cancer. This international, multicenter, open-label phase II study aims to assess the treatment response and the use of Quantum Optics technology on liquid biopsies to predict individual therapeutic responses. The study addresses the current challenge that only about half of patients benefit from this treatment combination, with no existing markers to identify responders beforehand. Participants will receive Palbociclib 125 mg daily, three weeks on and one week off, with dose adjustments as needed combined with an aromatase inhibitor Letrozole 2.5 mg or Anastrozole 1 mg daily. This treatment will continue until disease progression, typically over about two years. Premenopausal patients may also receive ovarian function suppression. Molecular fingerprinting by Quantum Optics will be performed on blood samples at enrollment, monthly for the first three months, and then every three months until relapse, alongside clinical and radiological evaluations every three months. During the study, participants will undergo regular clinical and radiological assessments based on Revised RECIST guidelines to monitor treatment response every three months for up to two years. Blood tests for plasma molecular fingerprinting will help predict treatment efficacy. Researchers will measure objective clinical response rates, progression-free survival, clinical benefit, and safety throughout treatment. The study also explores the role of molecular fingerprinting in predicting early progression and relapse, with ongoing safety monitoring until progression or study end.

Researchers are studying prostate cancer patients in Algeria to describe their demographic, clinical, diagnostic, and treatment characteristics. This observational study focuses on patients with confirmed prostate cancer and aims to analyze how the disease is diagnosed and managed in local oncology centers. Data will be collected through medical records and patient interviews lasting about 30 minutes. The study plans to enroll up to 500 patients and will use a standardized electronic form to gather information on medical history, clinical features, diagnostic tests, and treatment methods. All collected data will be anonymized for research purposes. Participants will undergo a one-time evaluation including interviews and medical record reviews. Researchers will assess socio-demographic details, family cancer history, lifestyle factors like smoking and alcohol use, symptoms, diagnostic procedures, and treatment approaches. The main outcomes include symptom scores and disease status at the initial visit. The study will also monitor time intervals from symptom onset to diagnosis and treatment, and track any adverse events reported by patients.